SCHEMBL1684609

SCHEMBL1684609

Cc1nc2ncccn2c1-c1ccnc(Nc2ccc(N(C)C)cc2)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.67
ALDH1A1 P00352 4/20 0.67
GAA P10253 4/20 0.67
RAB9A P51151 2/20 0.67
L3MBTL1 Q9Y468 2/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
CDK2 P24941 10/20 0.56
CDK4 P11802 6/20 0.56
CCNE1 P24864 5/20 0.56
CDK1 P06493 2/20 0.54
AURKA O14965 1/20 0.54
CDK7 P50613 1/20 0.54
CDK9 P50750 1/20 0.54
AURKB Q96GD4 1/20 0.54
KDM4E B2RXH2 3/20 0.53
MAPK1 P28482 3/20 0.53
LMNA P02545 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1684656 0.89 MAPT (0.65) MAPTALDH1A1GAARAB9AL3MBTL1
SCHEMBL1684728 0.87 CDK2 (0.58) MAPTALDH1A1GAARAB9AL3MBTL1
SCHEMBL1684749 0.87 CDK2 (0.58) MAPTALDH1A1GAARAB9AL3MBTL1
SCHEMBL1684684 0.85 CDK2 (0.79) MAPTALDH1A1GAARAB9AL3MBTL1
SCHEMBL1684528 0.85 MAPT (0.67) MAPTALDH1A1GAARAB9AL3MBTL1
SCHEMBL7980905 0.83 CDK2 (0.57) MAPTALDH1A1GAARAB9AL3MBTL1
SCHEMBL1684689 0.83 CDK2 (0.54) MAPTALDH1A1GAARAB9AL3MBTL1
SCHEMBL1684778 0.83 CDK2 (0.54) MAPTALDH1A1GAARAB9AL3MBTL1
SCHEMBL1684781 0.82 CDK2 (0.53) MAPTALDH1A1GAARAB9AL3MBTL1
SCHEMBL10251884 0.82 MAPK8 (0.56) MAPTALDH1A1GAARAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP claimed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US claimed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US claimed
EP-2306836-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2011-04-13 EP claimed
WO-2010002985-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2010-01-07 WO claimed
EP-3111956-B1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2019-05-08 EP disclosed
EP-3111956-A1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2017-01-04 EP disclosed
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS BMI1, CREBBP, BAZ2A MAPT 4026/4885ALDH1A1 2357/4885GAA 3522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.